Crateva adansonii DC, an African ethnomedicinal plant, exerts cytotoxicity in vitro and prevents experimental mammary tumorigenesis in vivo

详细信息    查看全文

• 作者：Sté ; phane Zingue^a ; ^b ; ^c ; ^{stephanezingue@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Julia Cisilotto^c ; Alain Brice Tueche^a ; Anupam Bishayee^d ; Francine Azegha Mefegue^a ; Louis Pergaud Sandjo^c ; Chantal Beatrice Magne Nde^e ; Evelyn Winter^c ; Thomas Michel^f ; Derek Tantoh Ndinteh^g ; Charline Florence Awounfack^b ; Kevine Kamga Silihe^b ; Tito Tresor Melachio Tanekou^b ; Tâ ; nia Beatriz Creczynski-Pasa^c ; Dieudonné ; Njamen^b ; ^g ; ^{dnjamen@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ACN ; acetonitrile ; AI ; atherogenic index ; AIP ; atherogenic index of plasma ; ALT ; alanine transaminase ; AST ; aspartate transaminase ; BW ; body weight ; CA ; Crateva adansonii ; CTAB ; cetyl trimethyl ammonium bromide ; DCM ; dichloromethane ; DMEM ; Dulbecco&rsquo ; s Modified Eagle Medium ; DMBA ; 7 ; 12 dimethylbenz(a)anththracene ; DMSO ; dimethylsulfoxide ; ELSD ; evaporative light scattering detector ; ER ; estrogen receptor ; FA ; formic acid ; FBS ; fetal bovine serum ; HEPES ; 4-(2-hydroxyethyl)-1-piperazineethanes
• 刊名：Journal of Ethnopharmacology
• 出版年：2016
• 出版时间：22 August 2016
• 年：2016
• 卷：190
• 期：Complete
• 页码：183-199
• 全文大小：4120 K

文摘

Crateva adansonii DC is a plant traditionally used in Cameroon to treat constipation, asthma, snakebites, postmenopausal complaints and cancers.

Aim

The anticancer potential of the dichloromethane/methanol extract of C. adansonii stem barks was investigated using human breast cancer cell and 7,12 dimethylbenz(a)anththracene (DMBA)-induced mammary tumorigenesis model in rats.

Material and methods

The cytotoxicity of C. adansonii extract was assessed in vitro towards breast carcinoma (MCF-7 and MDA-MB-231) and non-tumoral cell lines (NIH/3T3 and HUVEC) by Alamar Blue assay. Furthermore, in vivo studies were performed on female Wistar rats treated either with C. adansonii extract at a dose of 75 or 300 mg/kg body weight or with tamoxifen (3.3 mg/kg body weight), starting 1 week prior DMBA treatment and lasted 12 weeks. The investigation focused on tumour burden, tumour DNA fingerprint, morphological, histological, hematological, and biochemical parameters.

Results

CC₅₀ values for the in vitro assays were 289 µg/mL against MCF-7 cells and >500 µg/mL in others cells, leading to a selectivity index ≥1.73. C. adansonii extract significantly (p<0.001) revealed in vivo the reduction of the cumulative tumour yield (87.23%), total tumour burden (88.64%), average tumour weight (71.11%) and tumour volume (78.07%) at the dose of 75 mg/kg as compared to DMBA control group. A weak effect was also observed at 300 mg/kg. This extract showed a moderate hyperplasia at the dose of 75 mg/kg while at 300 mg/kg no significant change was noted as compared to DMBA group. It protected rats from the DNA alteration induced by DMBA and increased antioxydant enzymes activities in mammary gland tissue homogenates. In addition, Ultra-High Performance Liquid Chromatography/ESI-QTOF-Mass Spectrometry analysis of C. adansonii extract detected structure-related of many well-known anticancer agents such as flavane gallate, flavonol, phenylpropanoïds, sesquiterpene derivatives, gallotannins and lignans. The LD₅₀ of C. adansonii was estimated to be greater than 5000 mg/kg.

Conclusions

These aforementioned results suggest that the C. adansonii extract may possess antitumor constituents, which could combat breast cancer and prevent chemically-induced breast cancer in rats.